Target Corporation reported its 57th consecutive year of dividend increases and called its SG&A rate 'flat.' But the FY2025 10-K reveals a $593 million interchange fee settlement masked a 30 basis point deterioration in the underlying cost base, adjusted operating income declined 14.2% — nearly twice the GAAP decline — and management's own $5 billion capex guide pushes projected free cash flow $538 million below the annual dividend. For the first time, Target must borrow to sustain the streak that defines it as an income stock.
International Flavors & Fragrances reported an operating loss of $382 million in FY 2025 — yet management called it 'solid performance.' The disconnect: 72% of IFF's $2.1 billion Credit Adjusted EBITDA comes from add-backs. At GAAP EBITDA of $580 million, leverage isn't 2.6x — it's 9.3x. With $3.84 billion in cumulative goodwill impairments across three reporting units, six divestitures in 18 months, and a dividend payout ratio of 161% at the already-cut level, IFF's 10-K documents a $26 billion acquisition being systematically dismantled to save the company it was supposed to transform.
Altria Group paid $4.16 per share in dividends on $4.12 per share in earnings — a 101% GAAP payout ratio that screams 'unsustainable.' But the 10-K tells a different story: free cash flow grew 5.4% to $9.1 billion, covering the dividend at 1.29x. Meanwhile, smokeable operating income grew for three consecutive years despite falling revenue, driven by a structural mechanism where settlement costs decline faster than volume. The paradox deepens with $2.1 billion in NJOY write-downs, on! losing the pouch race to ZYN, and Marlboro shedding 1.5 share points in a single quarter.
Ares Management reported a 1% GAAP operating margin on $4.76 billion in revenue — $46.9 million in operating income that makes a grocery store look profitable. But the same 10-K reveals $2,583 million in fee-related earnings hiding behind the GAAP facade, a 55:1 gap driven by $2.6 billion in partnership-structure consolidation costs. At 16.6x FRE with 30% growth and 61% margins, the stock looks cheap — until you account for $1.675 billion in contingent earnout liabilities due by June 2028, $1.38 billion in new floating-rate debt, and a $740 million SBC regime that persists for three more years.
Enbridge reported record adjusted EBITDA of C$20 billion in FY2025 and celebrated its 31st consecutive dividend increase. Revenue surged 22%. Net income jumped 40%. But the 10-K tells a different story: core pipeline toll revenue grew just 1.8%, more than half of revenue is zero-margin commodity pass-through, and the dividend consumed 278% of free cash flow.
The gap between these two narratives — management's DCF showing 1.5x coverage versus GAAP FCF showing 0.36x — comes down to C$7.8 billion in annual growth capex. Is it discretionary? The filing's C$18.3 billion in non-cancellable purchase commitments suggest much of it is not.
We decompose Enbridge's revenue quality, dividend mechanics, segment margins, and leverage trajectory using data from the 10-K, Q3 8-K, and Q2 10-Q to show what the earnings headline misses.
Pfizer reported $1.36 in GAAP earnings per share for FY2025 — while paying a negative effective tax rate for the third consecutive year. Strip the tax distortion and EPS falls to $1.04. But the Biopharma segment quietly earned $29.3 billion at a 47.9% margin, up 3.1 percentage points. The 10-K reveals two depletion clocks running simultaneously: $4.68B/year in intangible amortization mechanically lifting GAAP EPS, and $18.5B in patent cliff exposure destroying revenue — with the curves crossing in 2027-2028.
Kenvue reported 41% EPS growth in FY2025 — its best result since separating from Johnson & Johnson. But the metric management actually uses to evaluate the business declined 4.6%. The entire recovery traces to $860 million in non-recurring accounting items: impairment cessation, separation cost winddown, and stock compensation forfeitures. Meanwhile, the company's Skin Health & Beauty segment suffered a 30% two-year profit collapse, three product ingredient categories face simultaneous FDA and litigation scrutiny, and 96% of the company's cash sits overseas — while Kenvue pays out 107.6% of net income in dividends. This is the final independent 10-K of a $15.1 billion consumer health company that has already agreed to be absorbed by Kimberly-Clark for $48.1 billion.
United Parcel Service eliminated 48,000 positions, closed 93 buildings, and claimed $3.5 billion in cost savings in FY2025. Yet operating margin fell to 8.9%, free cash flow dropped 23% to $4.8 billion, and the company borrowed $4.2 billion while paying out 113% of FCF in dividends. Our analysis of the 10-K filing traces where the $3.5 billion went through a savings absorption waterfall and reveals why the 6.6% dividend yield is a leveraged bet on future margin expansion.